Vascular Biology |
From the Department of Cardiovascular Physiology, University of Goettingen, Goettingen, Germany.
Correspondence to Markus Hecker, PhD, Department of Cardiovascular Physiology, University of Goettingen, Humboldtallee 23, 37073 Goettingen, Germany. E-mail hecker{at}veg-physiol.med.uni-goettingen.de
| Abstract |
|---|
|
|
|---|
Key Words: blood pressure endothelin-1 endothelin B receptor gene expression graft failure
| Introduction |
|---|
|
|
|---|
Predominantly formed by endothelial cells, this 21amino acid peptide is not only a powerful vasoconstrictor but also a potent mitogen for vascular SMCs. It is derived from a 212amino acid precursor, prepro-ET-1, that is sequentially processed to big ET-1 and ET-1 by a furin-like protease and an endothelin-converting enzyme (ECE-1).3 4 ET-1 exerts its biological effects mainly through activation of two types of G-proteincoupled receptors, the endothelin A receptor (ETA-R) and endothelin B receptor (ETB-R).5 Although SMCs express both types of receptors, activation of the ETA-R appears to predominantly modulate SMC tone and proliferation in arteries, whereas in veins, ET-1 seems to exert these effects primarily through activation of the ETB-R.3 5 Endothelial cells also express an ETB-R, the activation of which promotes the release of nitric oxide and prostacyclin, thereby potentially limiting an excessive ETA-R and/or ETB-Rmediated SMC stimulation by ET-1.3 5 Thus far, it is not clear whether the receptors in endothelial cells and SMCs represent the same or subtypes of ETB-R.6
Cyclic stretch has been reported to enhance ET-1 peptide synthesis and prepro-ET-1 mRNA expression in cultured endothelial cells.7 8 9 In the vessel wall in situ, endothelial cells are not normally exposed to this hemodynamic force, because the bulk of the physiological increase in transmural pressure is transformed into a circumferential tensile strain that almost exclusively affects the SMCs.10 However, in situations in which the pressure-induced distension of the vessel wall is more pronounced and/or chronically elevated, as in aortocoronary venous bypass grafts, endothelial cells may also be deformed to a significant extent.
To investigate whether a pressure-induced increase in tensile strain also affects prepro-ET-1 gene expression in the vessel wall in situ, we have developed an experimental model in which isolated segments of the rabbit external jugular vein are perfused at different levels of intraluminal pressure. In addition, we have investigated whether the resulting distension of the vessel wall also affects the expression of ECE-1 or that of the 2 endothelin receptors and what kind of signaling mechanism is involved therein.
| Methods |
|---|
|
|
|---|
,9
-epoxymethano-prostaglandin
F2
(U46619) was kindly provided by The
Upjohn Co.
Experimental Model
Male New Zealand White rabbits (2.0±0.1 kg body weight, n=47)
were anesthetized intravenously with 60 mg/kg
pentobarbital sodium (Nembutal, Sanofi) and exsanguinated by cutting
through both the aorta and vena cava. The left and right external
jugular veins were dissected, cut to equal size, and cleansed of
adventitial adipose and connective tissue. These were cut in half, so
that a set of four segments from each animal could be mounted into a
specially designed 4-position perfusion chamber and stretched back to
their in situ length (17.7±0.7 mm, n=74) by the aid of moveable
cannulas, onto which the segments were tied (see Figure 1a
). Vessel diameter was
continuously monitored by video microscopy (Visitron Instruments). The
lumen of the segments and the surrounding tissue baths were
individually perfused (lumen 1 mL/min, bath 0.5 mL/min) with warmed
(37°C) oxygenated (lumen 75%
N2/20% O2/5%
CO2, PO2
140 mm Hg, PCO2 15 to 20
mm Hg, pH 7.4; bath 95% O2/5%
CO2, PO2
>300 mm Hg, PCO2 18 to 38
mm Hg, pH 7.4) Tyrodes solution of the following composition
(in mmol/L): Na+ 144.3,
K+ 4.0, Cl- 138.6,
Ca2+ 1.7, Mg2+ 1.0,
HPO42- 0.4,
HCO3- 19.9, and
D-glucose 10.0. An IPC roller pump (Ismatec) was used for
perfusion, pumping at a frequency of 1.33 Hz with a peak pulsatile
pressure of ±1 mm Hg. After an equilibration period of 30
minutes, the segments were perfused at 0, 5, or 20 mm Hg for 3 to
12 hours with the aid of an adjustable afterload device system (Hugo
Sachs Elektronik). Perfusion pressure without the afterload device was
monitored to be 0 to 1 mm Hg by using a pressure transducer
connected to a side arm of the outflow tubing (see Figure 1a
.)
In experiments with drug or vehicle treatment, the segments were
perfused with defined drug concentrations at a reduced flow rate (0.5
mL/min) for up to 1 hour directly after the resting phase. In another
series of experiments, the segments were mechanically denuded by gentle
abrasion with a roughened stainless steel cannula (2.0-mm OD) before
being mounted into the perfusion chamber. To make sure that the
endothelium had been successfully removed,
histological, reverse transcription (RT)polymerase
chain reaction (PCR), and superfusion bioassay analyses were
used (see below). At the end of the perfusion, the segments were
snap-frozen in liquid N2 and stored at
-80°C.
|
Superfusion Bioassay
Four ring segments (3 to 4 mm wide) were tested
simultaneously by mounting them between force transducers
and a rigid support for measurement of isometric force (TSE). The rings
were superfused at 1 mL/min with warmed (37°C),
oxygenated (95% O2/5%
CO2, PO2
400 mm Hg, PCO2 38 mm Hg,
pH 7.4) Krebs-Henseleit solution of the following composition (in
mmol/L): Na+ 144.0, K+ 5.9,
Cl- 126.9, Ca2+ 1.6,
Mg2+ 1.2,
H3PO4-
1.2, SO42- 1.2,
HCO3- 25.0, and
D-glucose 11.1. Passive tension was adjusted over a
30-minute equilibration period to 0.4±0.1 g (n=16).
Thereafter, the rings were preconstricted with 10 to 100 nmol/L U46619
to 0.9±0.1 g (n=16). To test whether the endothelium
was functionally intact, 1 and 10 nmol acetylcholine was applied as a
single injection (10 µL) into the superfusate during the
plateau phase of constriction, and the presence or absence of a
relaxant response was monitored with the aid of a digital PCoperated
analysis system (Biosys, TSE). Experiments with ET-1 or the
sarafotoxins were performed in the same manner, except that the
segments were not actively constricted with U46619.
RT-PCR Analysis
The frozen segments were minced under liquid
N2 with the aid of a mortar and a pestle. Total
RNA was isolated with the Qiagen RNeasy kit (Qiagen) followed by cDNA
synthesis with a maximum of 3 µg total RNA (determined
photometrically by measuring the optical density at 260 and 280 nm) and
200 U Superscript II reverse transcriptase (GIBCO, Life Technologies)
in a total volume of 20 µL according to the manufacturers
instructions. For normalization of cDNA load, 5 µL of the resulting
cDNA solution (corresponding to
75 ng) and 20 pmol of each primer
(corresponding to a final concentration of 0.4 µmol/L, GIBCO)
were used for elongation factor 1 (EF-1) PCR with 1 U Taq DNA
polymerase (GIBCO) in a total volume of 50 µL according to the
manufacturers instructions. PCR products were electrophoretically
separated on 1.5% agarose gels containing 0.1% ethidium bromide, and
the intensity of the detected bands was determined densitometrically to
adjust cDNA volumes for subsequent PCR analyses
by using a CCD-camera system and the One-Dscan
Gel analysis software (Scanalytics). PCR conditions described
for EF-1 were identical for the other gene products except for the
individual adjustment of cDNA volumes. All PCR reactions were performed
individually for each primer pair in a Hybaid OmnE thermocycler (AWG)
that was programmed as follows: a unique 2-minute period for complete
denaturation at 94°C in the beginning followed by a primer-specific
number of cycles of 30-second denaturation at 94°C, 30-second
annealing at 53°C to 60°C (see below), and 1-minute primer
extension at 72°C, with an additional 5 minutes at 72°C for final
extension in the end. Individual PCR conditions were as follows (where
two different sets of primers are used for detection of the same gene
product [prepro-ET-1, ETA-R, and
ETB-R], comparable results were obtained):
Prepro-ET-1: product size 517 bp, 33 cycles, annealing temperature 53°C, forward 5' TGCTCCTGCTCCTCGCTGAT 3', reverse 5' AAGAGCGAGTGAGAGAGTGA 3' (corresponding to nucleotide sequences 270 to 289 and 786 to 767 of the rabbit prepro-ET-1 gene, GenBank accession No. X59931); product size 499 bp, 30 cycles, 58°C, forward 5' GGAGTGTGTCTACTTCTGCCAC 3', reverse 5' GGGAAGAGAAAGAGCGAGTG 3' (nucleotide sequences 296 to 317 and 795 to 776, rabbit prepro-ET-1).
ECE-1: product size 309 bp, 29 cycles, 58°C, forward 5' GCACCCTCAAGTGGATGGAC 3', reverse 5' CCGGAAACACGA-TCTCGTTC 3' (nucleotide sequences 1425 to 1444 and 1734 to 1715, human ECE-1, Z35307).
ETA-R: product size 334 bp, 30 cycles, 58°C, forward 5' CAGGGCATCCTTTTGGCTGGCACTG 3', reverse 5' GCGCGT- TGGGGCCATTCCTCATAC 3' (nucleotide sequences 24 to 48 and 358 to 335, human ETAR, E07649); product size 188 bp, 30 cycles, 55°C, forward 5' CCTTATCTACGTGGTCATTGATCT 3', reverse 5' AAGCCACTGCTCTGTACCTG 3' (nucleotide sequences 421 to 444 and 608 to 589, rat ETA-R, M60786).
ETB-R: product size 446 bp, 33 cycles, 53°C, forward 5' GTGCTGGGGATCATCGGGAAC 3', reverse 5' TGAACGGGATGAAGCAAGCAG 3' (nucleotide sequences 570 to 590 and 1015 to 995, human ETB-R, E07650); product size 304 bp, 33 cycles, 53°C, forward 5' TGTTGGCTTCCCCTTCATCT 3', reverse 5' TGGAGCGGAAGTTGTCGTAT 3' (nucleotide sequences 1203 to 1219 and 1506 to 1487, rat ETB-R, X57764).
EF-1: product size 951 bp, 22 cycles, 58°C, forward 5' TGCCGTCCTGATTGTTGCTGC 3', reverse 5' ATCACGGACAGC GAAACGACC 3' (nucleotide sequences 346 to 366 and 1297 to 1276, rabbit EF-1, X62245).
CD31 (platelet and endothelial cell adhesion molecule-1[PECAM-1]): product size 362 bp, 30 cycles, 56°C, forward 5' AACTTCACCATCCAGAAGG 3', reverse 5' CACTGGTATTCCACGTCTT 3' (nucleotide sequences 1207 to 1225 and 1568 to 1550, human CD31, M28526).
Inducible nitric oxide synthase (iNOS): product size 576 bp, 30 cycles, 60°C, forward 5' CAGCTACTGGGTCAAAGACAAGAGG 3', reverse 5' TGCTGAGAGTCATGGAGCCG 3' (nucleotide sequences 543 to 567 and 1118 to 1099, rabbit iNOS, U85094).
To verify the identity of the amplification products with the designed primer pairs, we cloned and sequenced the ECE-1, ETA-R, ETB-R, and CD31 PCR products and found a 87% to 92% homology with the published sequences of the corresponding human and rat genes. Moreover, to ensure that the PCR amplification was indeed semiquantitative (ie, in the linear phase of the exponential amplification curve), several PCR runs were performed on each set of samples from one animal to establish the adequate numbers of cycles that usually corresponded to the number indicated above.
Measurements of ET-1 Tissue Concentrations
ET-1 was extracted from the weighted segments according to the
methods of Hisaki et al11 and Moreau et al12
with minor modifications. Briefly, the segments were individually
pulverized under liquid nitrogen and incubated with 1 mL
chloroform/methanol (2:1 [vol/vol]) for 18 hours at 0°C to 4°C.
After addition of 0.4 mL double-distilled water, vigorous mixing, and
brief centrifugation, the protein-containing interphase
was applied to a preactivated 500-mg Sep-Pak Vac C18 cartridge
(Waters). After washing with 1 mL of 4% glacial acetic acid (vol/vol),
5 mL double-distilled water, 1.5 mL ethyl acetate, and 24% ethanol in
4% glacial acetic acid (vol/vol), ET-1 was eluted from the cartridge
with 1.5 mL of 86% ethanol in 4% glacial acetic acid (vol/vol). After
removal of the solvent in an Univapo 150H Speed-Vac (Uniequip), the
nearly dried residues were dissolved in 250 µL assay buffer. The
concentration of ET-1 in these tissue extracts was determined by using
a commercially available ELISA kit (Amersham) according to the
manufacturers instructions. Overall recovery of ET-1 was 69.4%, and
interassay and intraassay variability was 15.3% and 11.7%,
respectively, as determined with tissue samples to which 1 nmol/L
authentic ET-1 had been added.
Statistical Analysis
Unless indicated otherwise, all data in the figures and text are
expressed as mean±SEM of n observations. Statistical evaluation was
performed by Student t test for unpaired data with the
Instat for Windows statistics software package (GraphPad Software Inc).
A value of P<0.05 was considered statistically
significant.
| Results |
|---|
|
|
|---|
Because of the rather small amounts of total RNA extractable from these
segments (<3 µg), RT-PCR analysis had to be used for
monitoring pressure-related changes in mRNA abundance. The mRNA level
of the housekeeping reference gene, EF-1, was not altered by an
increase in perfusion pressure under any of the experimental conditions
described below (see Figure 2a
).
Moreover, there was no apparent loss of endothelial
cells from the endothelium-intact perfused segments,
even after 12 hours exposure to 20 mm Hg, as judged by the
virtually constant mRNA level of the specific
endothelial cell marker, CD31 (Figure 2b
), and
the maintained relaxant response to acetylcholine in the superfusion
bioassay (not shown). In addition, endothelial cell
integrity was checked histologically in
paraffin-embedded hematoxylin/eosin-stained tissue sections of
formaldehyde-fixed segments (not shown). Even though the experiments
were not performed under sterile conditions, there was no
microscopically visible contamination at any time point, and as judged
by RT-PCR analysis, no expression of iNOS mRNA, an extremely
sensitive marker for the presence of bacterial
lipopolysaccharides, could be detected. On the other hand, iNOS
mRNA levels were significantly upregulated after 12 to 30 hours
exposure of the segments to tumor necrosis factor-
(1000 U/mL) and
interferon-
(200 U/mL, not shown).
|
Prepro-ET-1 Expression and ET-1 Synthesis
There was a distinct amount of prepro-ET-1 mRNA detectable in
endothelium-intact and -denuded segments (95±17% of
the mRNA level in intact segments, n=5) that remained virtually
constant when the endothelium-intact segments were
perfused at either 0 or 5 mm Hg for up to 12 hours (see Figure 3a
). Prepro-ET-1 expression was
significantly upregulated, on the other hand, when the segments were
perfused at 20 mm Hg for 3 to 12 hours (see Figure 4a
) or when they were first equilibrated
at 5 mm Hg for 3 hours and then exposed to 20 mm Hg for 6
hours (Figure 3a
). For reasons of simplicity, therefore, most of
the experiments described below were performed by comparing segments
perfused at 0 mm Hg with those perfused at 20 mm Hg.
|
|
The pressure-induced increase in prepro-ET-1 mRNA abundance seemed to
occur predominantly in the endothelium, because it was
strongly diminished after denudation of the segments (Figure 3b
). The modest, albeit nonsignificant, increase in prepro-ET-1
mRNA abundance after 6 hours exposure to 20 mm Hg in the denuded
segments, on the other hand, may have been the result of an incomplete
removal of the endothelium, in view of the fact that a
small amount of CD31 mRNA was still detectable in the denuded segments
(Figure 2b
insert).
In addition to the increase in prepro-ET-1 mRNA, the intravascular
concentration of ET-1 in the endothelium-intact
segments was also markedly elevated after 6 hours exposure to a
perfusion pressure of 20 mm Hg (Figure 3c
).
ECE-1, ETA, and ETB Receptor
Expression
In contrast to prepro-ET-1 mRNA and ET-1 peptide, no
pressure-induced increase in ECE-1 mRNA was detected in
endothelium-intact or -denuded segments (Figure 3a
and 3b
). Raising the perfusion pressure to 20
mm Hg for 3 to 12 hours also did not significantly affect
ETA-R mRNA abundance (see Figure 4b
and 4c
). In contrast, ETB-R mRNA levels were
markedly increased after 3 to 12 hours exposure to 20 mm Hg
(Figure 4a
) but not 5 mm Hg (Figure 4b
) This
pressure-induced increase in ETB-R mRNA abundance
was equally detected with rather different primer pairs designed from
the sequence of the human and rat ETB-R gene,
respectively. (ETB-R mRNA abundance [expressed
as percentage of the mRNA in segments perfused at 0 mm Hg] in
segments exposed to 20 mm Hg for 6 hours is as follows: 446-bp
PCR product, 684±76%, n=23; 304-bp PCR product, 631±56%,
n=23), and it occurred independently of the presence of an intact
endothelium (Figure 4c
). Basal
ETB-R expression also did not differ
significantly between denuded and endothelium-intact
segments (122±9% of the mRNA abundance in denuded segments, n=5).
There are no suitable antibodies for rabbit ETA-R
and ETB-R (Western blot analyses that
used two different anti-peptide antibodies raised in sheep [BioTrend,
Research Diagnostics Inc] and an anti-peptide antibody
directed against the intracellular C-terminus raised in rabbits
[courtesy of Dr C. Schröder, Institute for
Physiological Chemistry and Pathobiochemistry,
University of Mainz, Mainz, Germany] failed to detect a protein band
of the expected size, 47 to 49 kDa, in homogenates of the
rabbit jugular vein.) Because of this lack of suitable antibodies for
rabbit ETA-R and ETB-R and
the rather large amounts of protein required for receptor binding
assays, the superfusion bioassay method was used to confirm that in
addition to the pressure-induced increase in
ETB-R mRNA, there is a corresponding increase in
functional receptor protein. To this end, we determined whether the
constrictor response to ET-1, the mixed receptor
agonist,14 15 sarafotoxin 6b (S6b), or the specific
ETB-R agonist,14 15 sarafotoxin 6c
(S6c), differs between segments exposed to a perfusion pressure of 0
and 20 mm Hg for 3 to 6 hours. The threshold dose for
ET-1induced constriction of these segments was 30 pmol, irrespective
of the treatment. Both sarafotoxins elicited a constrictor response,
the magnitude of which was comparable to that of ET-1 (Figure 5
). The constrictor response to all 3
agonists up to a dose of 0.1 nmol (corresponding to a final
concentration of
100 nmol/L in the superfusate) was almost
completely abrogated (>93% inhibition, n=3) by superfusion of the
segments with the ETB-Rspecific
antagonist,13 14 BQ 788 (1 µmol/L),
whereas the ETA-Rspecific
antagonist, BQ 123(1 µmol/L), produced only a weak
inhibitory effect (<21% inhibition, n=3). Moreover, after
6 hours exposure to 20 mm Hg, the constrictor responses to ET-1
(Figure 5a
) and especially to S6b (Figure 5b
) were
significantly enhanced. Pressurizing of the segments for 3 hours also
markedly augmented the constrictor response to S6c, whereas there was
no such difference after 6 hours exposure to 20 mm Hg (Figure 5c
). This increased efficacy of S6c after 3 hours exposure to
20 mm Hg did not differ between
endothelium-intact and -denuded segments (not
shown).
|
Regulation of Pressure-Induced Gene Expression at the
Transcriptional Level
Blockade of RNA synthesis with actinomycin D (1 µmol/L)
completely abrogated the pressure-induced increase in prepro-ET-1 and
ETB-R mRNA (Figure 6
) as well as the pressure-induced
increase in intravascular ET-1 (Figure 6
insert). Basal
prepro-ET-1 (77±20% of control, n=5) and ETB-R
mRNA levels (86±25%, n=5), on the other hand, were not affected by
treatment with actinomycin D. The protein synthesis
inhibitor cycloheximide (1 µmol/L) had no
significant effect either on basal (not shown) or pressure-induced
expression of these gene products after 6 hours (for prepro-ET-1,
471±101% without cycloheximide versus 312±71% with cycloheximide;
for ETB-R, 257±85% without cycloheximide versus
330±77% with cycloheximide; n=3).
|
Role of Protein Kinases
Pretreatment of the segments with the protein kinase C (PKC)
inhibitor15 Ro 318220 (0.1 µmol/L)
for 1 hour had no significant effect on ECE-1 or
ETA-R mRNA levels under basal conditions and in
the presence of an elevated perfusion pressure (not shown). In
contrast, basal (20±9% and 6±2% of control, respectively; n=4,
P<0.05) and pressure-induced (Figure 7a
) prepro-ET-1 and
ETB-R mRNA levels were markedly reduced after
exposure to Ro 318220. The putatively c-Src familyspecific tyrosine
kinase inhibitor, herbimycin A (0.1
µmol/L),16 17 on the other hand, had no significant
effect on prepro-ET-1 and ETB-R abundance under
basal conditions (81±11% and 58±19% of control, respectively; n=3)
and after exposure to 20 mm Hg for 6 hours (Figure 7b
).
|
| Discussion |
|---|
|
|
|---|
In perfused blood vessels extended to in situ length, as was the case
in our experiments, circumferential strain (
) is expressed as
=(d-d0)/d0, where d is
diameter, d0 is diameter at 0 mm Hg (ie,
atmospheric pressure), and d-d0 is the
pressure-induced change in diameter.20 A large
vein, such as the rabbit jugular vein, is maximally distensible at an
intraluminal pressure of 4 to 5 mm Hg but becomes rather stiff at
pressures >15 mm Hg, when collagen takes over from elastin in
the vessel wall to balance the distending pressure.18 19 20
Such a stiffening and collagen alignment is also observed in the human
saphenous vein at arterial levels of blood
pressure.21 Monitoring by video microscopy of the outer
diameter of the perfused veins confirmed that there was indeed a much
greater distension between 0 and 5 mm Hg compared with 5 and
20 mm Hg. Moreover, significant changes in de novo ET-1 synthesis
and ETB-R expression were detectable only between
5 and 20 mm Hg, suggesting that the threshold for stretch-induced
gene expression in venous endothelial cells and SMCs is
either rather high or that these cells are deformed further by being
pushed into the stiffening collagen. Irrespective of the biomechanical
force ultimately being responsible for the pressure-induced increase in
gene expression, the present findings clearly demonstrate that such
an effect occurs only when the distending intraluminal pressure (ie,
blood pressure) is clearly elevated beyond the mean circulatory filling
pressure in veins (4 to 6 mm Hg).18 19 20 In contrast
to the situation in the rabbit and human jugular veins, the distal
portions of the saphenous vein routinely used for aortocoronary
bypass grafting experience much greater changes in blood pressure
between 5 and 10 mm Hg in the recumbent position and between 75
and 80 mm Hg on quiet standing (ie, without activation of the
muscle pump and at ambient temperature).22 However, this
hemodynamic pressure load (averaging 40 to 50
mm Hg over 24 hours)23 is by no means as constant as
after grafting of the saphenous vein into the coronary
circulation, where, in addition to the mean arterial blood
pressure of 90 to 100 mm Hg, the anastomosed segments are
additionally subjected to a significant outflow resistance, owing to
the fact that their lumen is usually much wider than that of the
bypassed coronary arteries. Thus, the range of intraluminal
pressures to which the isolated perfused rabbit jugular veins were
subjected in the present study can be regarded as principally
similar to the situation in aortocoronary venous bypass
grafts.
Because the pressure-induced increase in endothelial prepro-ET-1 mRNA and in ET-1 peptide synthesis was sensitive to actinomycin D (ie, blockade of mRNA synthesis), it would appear that the elevated perfusion pressure affects prepro-ET-1 mRNA synthesis rather than stability. Despite the lack of effect on ECE-1 mRNA abundance, we cannot completely discount the possibility of an additional pressure-induced increase in ECE-1 expression or activity. Three different splice variants of ECE-1 have been described,24 the expression of which may be differentially regulated. Our present RT-PCR protocol cannot differentiate between these splice variants, so that a note of caution may be appropriate regarding the pressure insensitivity of ECE-1 expression in rabbit blood vessels. On the other hand, the pressure-induced rise of prepro-ET-1 mRNA was accompanied by an even higher increase in the intravascular concentration of ET-1, suggesting that ECE-1 activity or expression may not be a rate-limiting factor in ET-1 synthesis in response to a pressure-dependent deformation of the endothelial cells.
In addition to the increase in prepro-ET-1 expression in the endothelium, increasing the perfusion pressure beyond 5 mm Hg also significantly upregulated ETB-R but not ETA-R expression in the isolated perfused rabbit jugular vein independently of the presence of an intact endothelium. This pressure-induced ETB-R expression was confirmed at the mRNA level with two completely different PCR products obtained with primer pairs designed from the sequences of the human and rat ETB-R gene, respectively. Moreover, it appeared to be controlled at the level of transcription, in view of the fact that it was abolished by actinomycin D.
To demonstrate that the observed pressure-induced increase in
ETB-R mRNA also translated into an increase in
ETB-R protein, the superfusion bioassay technique
that enabled us to measure specific alterations in endothelin
receptor-mediated responses was used. We could confirm previous
findings of the rabbit jugular vein behaving as a pure
ETB-R preparation,13 14 even in the
presence of S6b, which may be explained by the known lack of
selectivity of this receptor for ET-1, ET-2, ET-3, and the
sarafotoxins. However, there was a difference between the two
sarafotoxins that might be related to a higher efficacy of S6b compared
with S6c in the presence of endogenously synthesized ET-1.
Thus, the pressure-induced potentiation of
ETB-Rmediated vasoconstriction (indicative of
an increase in ETB-R protein abundance) after 6
hours exposure to 20 mm Hg was observed with S6b but not S6c.
However, when the segments were pressurized for 3 hours (ie, when the
pressure-induced increase in prepro-ET-1 mRNA abundance was still
rather small; see Figure 4a
), the potentiation of the
constrictor response to S6c was comparable to that of S6b after 6 hours
exposure to 20 mm Hg. Therefore, it may be that the
ETB-R is rapidly desensitized by
endogenous ET-125 and that this
desensitization (or shift in affinity) can be overcome by S6b but not
S6c. Notwithstanding these considerations, the superfusion
bioassay data demonstrate that the pressure-induced increase in
ETB-R mRNA abundance in the isolated perfused
rabbit jugular vein is accompanied by an increase in functional
ETB-R protein.
Circumferential strain has been linked to gene expression in vascular
cells by two major signaling pathways that may join at the level of Raf
kinase, ie, the phospholipase CPKC and the c-SrcRas
pathway.26 In a first attempt to elucidate the signal
transduction pathway involved in pressure-induced gene expression, Ro
318220, a highly selective inhibitor of PKC
,
PKCßI, PKCßII, PKC
,
and PKC
with IC50 values ranging from 5 to 27
nmol/L,15 was used. Ro 318220 completely abrogated the
pressure-induced increase in prepro-ET-1 mRNA abundance, supporting
previous results of a PKC-mediated release of ET-1 from cultured
endothelial cells in response to cyclic
strain.9 Moreover, PKC blockade also abolished the
pressure-induced rise in ETB-R mRNA. In contrast,
exposure of the segments to herbimycin A had no such effect. At the
concentration used (100 nmol/L), herbimycin A appears to be highly
specific for the c-Src family of tyrosine kinases and does not affect
the activity of other tyrosine kinases.16 17 It would
appear, therefore, that in endothelial cells and in
SMCs of the rabbit jugular vein, activation of one or several isoforms
of PKC is crucial for the pressure-induced increase in gene
expression.
In addition to providing a basis for a more detailed investigation of the signaling mechanisms involved in pressure-induced gene expression in the vessel wall in situ, the aforementioned findings raise the question as to what the functional consequences of the upregulation of ET-1 synthesis and ETB-R expression in response to a maintained supraphysiological pressure level are. One distinct possibility is that this may lead to excessive vasoconstriction and hence to the vasospasm that is frequently observed in acute graft failure, especially because ETB-Rmediated vasoconstriction is usually observed in veins only.5 Moreover, venous but not arterial SMCs in culture have been reported to proliferate in response to cyclic strain.27 28 This effect could also be triggered by ET-1 via the ETB-R29 and thus contribute to the intimal hyperplasia of venous bypass grafts, which in up to 35% of patients with coronary heart disease causes their failure 1 year after the surgical intervention.
However, there are other reports of an increased ETA-R expression in porcine saphenous veincarotid artery interposition grafts 1 month after surgery,30 a downregulation of ETB-R in rabbit saphenous vein-carotid artery interposition grafts 1 month after surgery,31 and no apparent change in ETA-R and ETB-R distribution but an enhanced ETA-Rmediated sensitivity to ET-1 in human aortocoronary saphenous vein grafts several years after surgery.32 In a related setting of pressure-induced gene expression (ie, angioplasty), on the other hand, evidence has been provided that points to an important role for the ETB-R or a nonETA-R/nonETB-R in the rabbit33 and rat carotid artery34 35 36 in restenosis. Therefore, further studies in an appropriate animal model (ie, jugular veincarotid artery interposition graft) are required to substantiate the hypothesis of an ET-1induced ETB-Rmediated proliferative response in aortocoronary venous bypass grafts. The timing of these experiments may turn out to be crucial because the pressure-induced increase in smooth muscle ETB-R expression in the rabbit jugular vein appeared to be a transient phenomenon.
In summary, the aforementioned findings reinforce the notion of a pressure-induced rise in endothelial ET-1 synthesis along with an increased expression of the ETB-R in the smooth muscle of the rabbit jugular vein. Provided that such blood pressureinduced changes in gene expression also occur in the human saphenous vein in vivo, they may well contribute to the acute or intermediate failure of aortocoronary venous bypass grafts. Therefore, it may be advantageous to reevaluate the therapeutic benefit of a selective ETB-R or a mixed ETA-R/ETB-R antagonist in these conditions.
| Acknowledgments |
|---|
Received February 24, 1999; accepted July 1, 1999.
| References |
|---|
|
|
|---|
2. Brody JI, Capuzzi DM, Fink GB. In situ endothelin in coronary artery disease. Angiology.. 1996;47:10271032.
3. Parris RJ, Webb DJ. The endothelin system in cardiovascular physiology and pathophysiology. Vasc Med. 1997;2:3143.[Medline] [Order article via Infotrieve]
4. Schiffrin, EL, Intengan HD, Thibault G, Touyz RM. Clinical significance of endothelin in cardiovascular disease. Curr Opin Cardiol. 1997;12:354367.[Medline] [Order article via Infotrieve]
5. Douglas SA, Ohlstein EH. Signal transduction mechanisms mediating the vascular actions of endothelin. J Vasc Res. 1997;34:152164.[Medline] [Order article via Infotrieve]
6. Clozel M, Gray GA. Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol. 1995;26(suppl 3):S262S264.
7. Sumpio BE, Widmann MD. Enhanced production of endothelium-derived contracting factor by endothelial cells subjected to pulsatile stretch. Surgery. 1990;108:277281.[Medline] [Order article via Infotrieve]
8. Macarthur H, Warner TD, Wood EG, Corder R, Vane JR. Endothelin-1 release from endothelial cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. Biochem Biophys Res Commun. 1994;200:395400.[Medline] [Order article via Infotrieve]
9. Wang DL, Wung BS, Peng YC, Wang JJ. Mechanical strain increases endothelin-1 gene expression via protein kinase C pathway in human endothelial cells. J Cell Physiol. 1995;163:400406.[Medline] [Order article via Infotrieve]
10.
Davies PF. Flow-mediated endothelial
mechanotransduction. Physiol Rev. 1995;75:519560.
11.
Hisaki K, Matsumura Y, Maekawa H, Fujita K, Takaoka M,
Morimoto S. Conversion of big ET-1 in the rat lung: role of
phosphoramidon-sensitive endothelin-1-converting
enzyme. Am J Physiol. 1994;266:H422H428.
12.
Moreau P, dUscio LV, Shaw S, Takase H, Barton M.
Lüscher TF. Angiotensin II increases tissue
endothelin and induces vascular hypertrophy.
Circulation. 1997;96:15931597.
13. White DG, Cannon TR, Garratt H, Mundin JW, Sumner MJ, Watts IS. Endothelin ETA and ETB receptors mediate vascular smooth-muscle contraction. J Cardiovasc Pharmacol. 1993;22:S144S148.
14. Lodge NJ, Halaka NN. Endothelin receptor subtype(s) in rabbit jugular vein smooth muscle. J Cardiovasc Pharmacol. 1993;22:S140S143.
15. Wilkinson SE, Parker PJ, Nixon JS. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J. 1993;294:335337.
16. Takahashi M, Berk BC. Mitogen-activated protein kinase (ERK1/2) activation by shear stress and adhesion in endothelial cells: essential role for a herbimycin-sensitive kinase. J Clin Invest. 1996;98:26232631.[Medline] [Order article via Infotrieve]
17. Hall TJ, Schaeublin M, Missbach M. Evidence that c-src is involved in the process of osteoclastic bone resorption. Biochem Biophys Res Commun. 1994;199:12371244.[Medline] [Order article via Infotrieve]
18.
Moreno AH, Katz AI, Gold LD, Reddy RV. Mechanics of
distension of dog veins and other very thin-walled tubular structures.
Circ Res. 1970;27:10691080.
19. Caro CG, Pedley TJ, Schroter RC, Seed WA. The Mechanics of the Circulation. Oxford, UK: Oxford University Press; 1978.
20. Dobrin PH. Vascular mechanics. In: Shepherd JT, Abboud FM, eds. Handbook of Physiology, Section 2: The Cardiovascular System, Volume III, Peripheral Circulation and Organ Blood Flow. Bethesda, Md: American Physiological Society; 1983:65102.
21.
Canham PB, Finlay HM, Boughner DR. Contrasting
structure of the saphenous vein and internal mammary artery used as
coronary bypass vessels. Cardiovasc Res. 1997;34:557567.
22. Stick C, Hiedl U, Witzleb E. Venous pressure in the saphenous vein near the ankle during changes in posture and exercise at different ambient temperatures. Eur J Appl Physiol. 1993;66:434438.
23. Noddeland H, Ingemansen R, Reed RK, Aukland K. A telemetric technique for studies of venous pressure in the human leg during different positions and activities. Clin Physiol. 1983;3:573576.[Medline] [Order article via Infotrieve]
24. Schweizer A, Valdenaire, O, Nelbock P, Deuschle U, Dumas Milne Edwards JB, Stumpf JG, Löffler BM. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J. 1997;328:871877.
25. Owe-Young R, Schyvens CG, Qasabian RA, Conigrave AD, Macdonald PS, Williamson DJ. Transcriptional down-regulation of the rabbit pulmonary artery endothelin B receptor during phenotypic modulation. Br J Pharmacol. 1999;126:103110.[Medline] [Order article via Infotrieve]
26.
Lehoux S, Tedgui A. Signal transduction of mechanical
stresses in the vascular wall. Hypertension. 1998;32:338345.
27. Predel HG, Yang Z, von Segesser L, Turina M, Bühler FR, Lüscher TF. Implications of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle. Lancet. 1992;340:878879.[Medline] [Order article via Infotrieve]
28. Dethlefsen SM, Shepro D, DAmore PA. Comparison of the effects of mechanical stimulation on venous and arterial smooth muscle cells in vitro. J Vasc Res. 1996;33:405413.[Medline] [Order article via Infotrieve]
29. Porter KE, Olojugba DH, Masood I, Pemberton M, Bell PRF, London NJM. Endothelin-B receptors mediate intimal hyperplasia in an organ culture of human saphenous vein. J Vasc Surg. 1998;28:695701.[Medline] [Order article via Infotrieve]
30. Dashwood MR, Mehta D, Izzat MB, Timm M, Bryan AJ, Angelini GD, Jeremy JY. Distribution of endothelin-1 (ET) receptors ET(A) and ET(B) and immunoreactive ET-1 in porcine saphenous vein-carotid artery interposition grafts. Atherosclerosis. 1998;137:233242.[Medline] [Order article via Infotrieve]
31.
Eguchi D, Nishimura J, Kobayashi S, Komori K, Sugimachi
K, Kanaide H. Down-regulation of endothelin B receptors in autogenous
saphenous veins grafted into the arterial circulation.
Cardiovasc Res. 1997;35:360367.
32. Maguire JJ, Davenport AP. Endothelin receptor expression and pharmacology in human saphenous vein graft. Br J Pharmacol. 1999;126:443450.[Medline] [Order article via Infotrieve]
33. Azuma H, Hamasaki H, Sato J, Isotani E, Obayashi S, Matsubara O. Different localization of ETA and ETB receptors in the hyperplastic vascular wall. J Cardiovasc Pharmacol. 1995;25:802809.[Medline] [Order article via Infotrieve]
34.
Wang X, Douglas SA, Louden C, Vickery-Clark LM,
Feuerstein GZ, Ohlstein EH. Expression of endothelin-1, endothelin-3,
endothelin-converting enzyme-1, and endothelin-A and endothelin-B
receptor mRNA after angioplasty-induced neointimal
formation in the rat. Circ Res. 1996;78:322328.
35. Tsujino M, Hirata Y, Eguchi S, Watanabe T, Chatani F, Marumo F. Nonselective ETA/ETB receptor antagonist blocks proliferation of rat vascular smooth muscle cells after balloon angioplasty. Life Sci. 1995;56:449454.
36. Douglas SA, Vickery-Clark LM, Louden C, Ohlstein EH. Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat. Cardiovasc Res. 1995;29:641646.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
Z. Jiang, P. Yu, M. Tao, C. Fernandez, C. Ifantides, O. Moloye, G. S. Schultz, C. K. Ozaki, and S. A. Berceli TGF-beta- and CTGF-mediated fibroblast recruitment influences early outward vein graft remodeling Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H482 - H488. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Kapur, C. B. Deming, S. Kapur, C. Bian, H. C. Champion, J. K. Donahue, D. A. Kass, and J. J. Rade Hemodynamic Modulation of Endocardial Thromboresistance Circulation, January 2, 2007; 115(1): 67 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Filippi, A. Morelli, L. Vignozzi, G. B. Vannelli, M. Marini, P. Ferruzzi, R. Mancina, C. Crescioli, N. Mondaini, G. Forti, et al. Oxytocin Mediates the Estrogen-Dependent Contractile Activity of Endothelin-1 in Human and Rabbit Epididymis Endocrinology, August 1, 2005; 146(8): 3506 - 3517. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lauth, M. Cattaruzza, and M. Hecker ACE Inhibitor and AT1 Antagonist Blockade of Deformation-Induced Gene Expression in the Rabbit Jugular Vein Through B2 Receptor Activation Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 61 - 66. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. CATTARUZZA, C. DIMIGEN, H. EHRENREICH, and M. HECKER Stretch-induced endothelin B receptor-mediated apoptosis in vascular smooth muscle cells FASEB J, May 1, 2000; 14(7): 991 - 998. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |